PSS26 EXPECTED VALUE OF PARTIAL PERFECT INFORMATION IN A MARKOV MODEL OF INFLIXIMAB AND ETANERCEPT IN THE TREATMENT OF MODERATE TO SEVERE PLAQUE TYPE PSORIASIS  by Visser, MS
Paris Abstracts A457
more effective and less costly than latanoprost (25.68% vs. 24.76% IOP reduction 
rate, $603.08 vs. $615.33 expected cost). Thus taﬂuprost was shown to be dominant 
compared with latanoprost. The results of sensitivity analysis revealed stable across 
most of the included parameters. CONCLUSIONS: According to this study, taﬂuprost 
shows better clinical outcome for one year than latanoprost. In addition, frist-line 
treatment of taﬂuprost is a more cost-effective strategy associated with POAG or 
ocular hypertension compared with latanoprost.
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OBJECTIVES: The objective of this study was to evaluate the cost-effectiveness (CE) 
of biologic drugs for the treatment of moderate to severe psoriasis. METHODS: A 
CE model was developed to estimate the incremental cost per quality adjusted life-year 
(QALY) associated with supportive care and each biologic for the treatment of moder-
ate to severe psoriasis (deﬁned by 4th quartile DLQI for purposes of calculating utili-
ties). Treatments were compared using the Psoriasis Area Severity Index (PASI) 50, 
75, and 90 response rates at 10 weeks for inﬂiximab and 12 weeks for the others, 
which were supported by clinical trials and an expert panel. Direct health care costs 
and utilities values were also included in the analysis. The CE analysis was conducted 
by comparing estimates of expected costs and health effects per unit of time for each 
treatment, incorporating both patients who ‘respond’ and continue treatment and 
those who do not ‘respond’ and stop treatment. All data was reviewed by a focus 
group in order to adapt the model to the Spanish clinical practice RESULTS: In the 
base case analysis inﬂiximab is associated with mean expected costs of a5909 and 
mean expected QALYs of 0.216. Respective results were a2947 and 0.100 QALYs 
for etanercept 25 mg, a5433 and 0.173 QALYs for adalimumab and a7,907 and 0,151 
QALYs for etanercept 50 mg. The incremental cost-effectiveness ratio (ICER) was 
a27,320 for inﬂiximab, a29,430 for etanercept, a31,417 for adalimumab and a52,367 
for etanercept 50 mg. CONCLUSIONS: First Inﬂiximab 5 mg/kg (0,2,6 then every 8 
weeks) and then etanercept 25 mg administered twice a week treatments are the most 
cost-effective alternatives from the Spanish National Health System perspective for the 
treatment of moderate to severe psoriasis, both below the a30,000/QALY threshold 
commonly accepted in Spain for the introduction of new technologies.
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OBJECTIVES: The objective of the ‘piggy-back’ trial is to examine the cost-effective-
ness of inﬂiximab compared to etanercept in patients with moderate to severe plaque    
psoriasis or psoriasis vulgaris. Before starting the cost-effectiveness study it is usefull 
to know what to measure and where to invest or aim for. The objective of this paper     
is to estimate the expected value of perfect information (EVPI), with an underlying 
goal of estimating the partial EVPI’s (EVPPI’s) to make a prediction about the value 
of obtaining further information, for all parameters and a partial set of parameters. 
METHODS: Analysis was conducted using a Markov model for patients with moder-
ate to severe plaque psoriasis. For estimating partial EVPI’s (EVPPI’s) a Monte Carlo 
simulation (MCS) method was used. Transition probabilities were calculated, based 
on published evidence, expert opinion, and demographic data. Outcomes expected 
were total societal costs, expected QALY’s and clinical effectiveness. The analysis was 
performed from a partial societal perspective of The Netherlands. The outcome of 
partial EVPI was split into costs, utilities, success rates and dropout rates. RESULTS: 
The cost-effectiveness acceptability curve (CEAC) indicates a high decision uncer-
tainty. The CEAC and EVPI also show inﬂiximab needs a high willingness to pay. 
According to the EVPPI analysis the most uncertainty is seen in utilities (25,239 
million) followed by costs (a4,216 million). Success rates and dropout rates also show 
a high EVPPI but much lower (around 204 and 385 million). CONCLUSIONS: When 
looking at the EVPPI’s there is clearly much interest in investing in research to the 
utilities and the cost of treatment and little interest investing in success rates and 
progress rates. Because indirect costs, like costs of travel and productivity loss, are 
excluded and differ between the two therapies, there can be potential gain by further 
research to the costs.
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OBJECTIVES: Biologic therapies have proven efﬁcacious for patients with moderate-
to-severe psoriasis. However, recommended therapeutic regimens and modes of 
administration differ from agent to agent. For Italy, their economic value compared 
with standard of care has not been explored. This study estimates the cost-effectiveness 
of intermittent therapy with etanercept in patients with moderate-to-severe plaque-
type psoriasis in comparison with non-systemic therapy in Italy. METHODS: This 
study employs cost-utility analysis using a Markov model adapted from the British 
“York model”. It compares intermittent etanercept vs non-systemic therapy in terms 
of cost per Quality-Adjusted Life Year (QALY). Data on efﬁcacy and changes in 
quality of life were derived from three etanercept clinical trials. Direct costs of treating 
psoriasis patients, including hospitalizations and dermatology clinic visits, were taken 
from an Italian cost-of-illness study. Extrapolations were made to evaluate the 
cost-effectiveness of intermittent etanercept vs non-systemic therapy over a period of 
ten years. RESULTS: For the group of patients with moderate and severe plaque 
psoriasis (initial Psoriasis Area and Severity Index PASI q 10) the incremental cost-
effectiveness ratio (ICER) for etanercept compared with non-systemic therapy 
was a33,216/QALY; for the group of patients with severe psoriasis (PASI q 20), the 
ICER was a25,486/QALY. CONCLUSIONS: Within the Italian health care system, 
intermittent etanercept (25 mg twice weekly) is a cost-effective therapeutic option 
compared with non-systemic therapy for the group of patients with moderate and 
severe plaque psoriasis. For patients with PASI q 20 etanercept cost-effectiveness is 
even greater.
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OBJECTIVES: To determine the cost-effectiveness of ustekinumab versus etanercept 
among Canadian adults with severe plaque psoriasis who have an inadequate response, 
are intolerant or contraindicated to at least one conventional systemic therapy. 
METHODS: The York Model, developed to evaluate biologics for the National 
Institute for Health and Clinical Excellence, was adapted to the Canadian environ-
ment. The model consisted of an initial 12-week trial period based on results from 
ACCEPT, an active-control phase III trial which demonstrated superior efﬁcacy of 
ustekinumab versus etanercept. The maintenance period, consisted of the trial results 
extrapolated over a 10-year time horizon. The cost-utility analysis compared estimates 
of expected costs and health effects of ustekinumab 45 mg q12w and etanercept 50 mg       
biw for 12 weeks and qw thereafter. Response was deﬁned as achievement of qPASI 
75 from the ACCEPT trial. Non-responders were switched to supportive care. 
Resource utilization was obtained from the literature and a Delphi panel of Canadian 
dermatologists. Direct health care costs were obtained from the literature and expert 
opinion. Utility was mapped from DLQI to EQ-5D using the algorithm used by the 
York Model. Costs and outcomes were discounted at 5%. RESULTS: Mean annual 
costs and QALYs for ustekinumab were $16,835 and 0.1464 compared to $19,558 
and 0.1419 for etanercept. These results were robust to changes in parameter esti-
mates. Not knowing the costs of adverse events over the 10-year time horizon was a 
limitation of the analysis. Cost-effectiveness acceptability curves show that at all levels 
of willingness- to-pay for one additional unit of efﬁcacy, ustekinumab 45 mg remains   
a more cost-effective treatment option than etanercept. CONCLUSIONS: Ustekinumab 
was more effective and less costly than etanercept over a 10-year time horizon, sug-
gesting that ustekinumab is a dominant treatment option relative to etanercept for the 
treatment of patients with severe plaque psoriasis.
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BACKGROUND: Lack of adherence to drug treatment is a major obstacle to disease 
control. Persistence and compliance are two components of adherence. OBJECTIVES: 
to assess: 1) the proportion of antiglaucoma medication users who persist on their 
treatment after 12 months; 2) the proportion of compliant users among them; and 3) 
the determinants of persistence and of compliance. METHODS: A population-based 
cohort study using the Quebec Health Insurance Board databases. Patients initiated 
on antiglaucoma medication treatment between January 1, 1998, and January 6, 2007 
were included. Patients still undergoing treatment with any antiglaucoma medication 
1 year after their ﬁrst prescription were considered persistent. Of these patients, those 
with a supply of drugs for at least 80% of the days were deemed compliant. A multi-
variate logistic regression model using a stepwise procedure was used to identify the 
characteristics associated with both outcomes. RESULTS: Of 69,461 new users of 
antiglaucoma medication, 41,005 (59%) were persistent after 1 year, and 16,592 
(40.5% of those who persisted) were compliant. Patients more likely to be both per-
sistent and compliant were female and those whose ﬁrst prescription was made by an 
ophthalmologist. Increasing age, living in a rural area, and having initiating glaucoma 
treatment after 2002 were associated with persistence, whereas having used more than 
ﬁve prescription drugs in the year preceding antiglaucoma treatment initiation was 
associated with better compliance. Patients initiated on sympathomimetics, parasym-
pathomimetics, carbonic anhydrase inhibitors, beta blocking agents and on more than 
